AAOS on IPO Elimination Reversal in 2022 CMS Outpatient Rule

American Association of Orthopaedic Surgeons (AAOS) President Daniel K. Guy, MD, FAAOS, issued the following statement in response to the newly released Calendar Year (CY) 2022 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Most notably, the Centers for Medicare & Medicaid Services (CMS) is proposing to halt the elimination of the Inpatient Only (IPO) list and place the 298 services that were previously removed back onto the list beginning in CY 2022.

“AAOS is encouraged to hear that CMS has heeded the patient safety concerns of the physician community regarding the abrupt elimination of the Inpatient Only (IPO). We continue to support the removal of procedures which have been proven to be done safely in the outpatient setting; however, there is much work left to be done to clarify what these changes mean in order to avoid widespread confusion and unintended consequences for patient care. Orthopaedic surgeons know firsthand from their experience with total knee arthroplasty removal in 2018, total hip arthroplasty in 2020, and then the removal of all musculoskeletal procedures in 2021 how challenging such a dramatic shift can be to safe and timely musculoskeletal care.

“Now as the agency reassess how it will evaluate future procedures for removal and the longer-term plan for the IPO, it should place more emphasis on physicians leading those decisions and prioritize the value of patient choice. CMS must also be careful to avoid creating new regulatory barriers to determining the appropriate setting of care as an overcorrection to the policy reversal—especially now after the country has benefited from such flexibilities and individualized medicine during the COVID-19 pandemic.

“Transparency around these changes and input from the medical community are critical to the successful implementation of the rule. We look forward to commenting on the proposal in greater detail and offering our formal comments later this year on behalf of the musculoskeletal community.”

Hot this week

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.